Lataa...
Phase I Trial of Prophylactic Donor-Derived IL-2-Activated NK Cell Infusion after Allogeneic Hematopoietic Stem Cell Transplantation from a Matched Sibling Donor
SIMPLE SUMMARY: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a curative option for high-risk hematologic malignancies. However, disease recurrence after allo-HSCT remains a critical issue, underlining the need to develop maintenance therapy. In this context, NK cell-based immuno...
Tallennettuna:
| Julkaisussa: | Cancers (Basel) |
|---|---|
| Päätekijät: | , , , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
MDPI
2021
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8198961/ https://ncbi.nlm.nih.gov/pubmed/34071607 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13112673 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|